MDxHealth (NASDAQ:MDXH) Announces Earnings Results

Posted by George Bondi on May 15th, 2026

MDxHealth (NASDAQ:MDXH – Get Free Report) issued its earnings results on Wednesday. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05), FiscalAI reports. The company had revenue of $23.90 million during the quarter, compared to analyst estimates of $30.89 million. MDxHealth had a negative net margin of 31.07% and a negative return on equity of 1,078.01%.

Here are the key takeaways from MDxHealth’s conference call:

MDxHealth will discontinue its Resolve UTI business and shut the Plano lab, citing an increasingly uncertain reimbursement environment and a recent Novitas policy reversal.
The company said Novitas is seeking up to $10.4 million in recoupments of historical Resolve claims, which MDxHealth is disputing through the Medicare appeals process.
Q1 2026 revenue was $27.4 million as reported, or $23.9 million on a pro forma basis excluding Resolve, which management said represented 11% growth in the core prostate cancer business.
Pro forma operating loss widened to $7.9 million from $4.7 million a year ago, while pro forma net loss was $9.4 million, reflecting the added impact of the ExoDx acquisition.
Management reaffirmed its focus on prostate cancer diagnostics and raised 2026 revenue guidance for the core business to $110 million-$115 million, implying 20%-26% year-over-year growth.

MDxHealth Price Performance

Shares of NASDAQ MDXH traded down $0.09 during midday trading on Friday, hitting $0.90. 3,209,374 shares of the company’s stock were exchanged, compared to its average volume of 329,071. MDxHealth has a twelve month low of $0.68 and a twelve month high of $5.33. The firm has a market cap of $44.45 million, a P/E ratio of -1.34 and a beta of 1.60. The stock’s 50 day moving average price is $2.47 and its 200-day moving average price is $3.25.

Institutional Trading of MDxHealth

Hedge funds have recently added to or reduced their stakes in the business. Kennedy Capital Management LLC bought a new position in shares of MDxHealth in the third quarter worth $1,826,000. FreeGulliver LLC raised its stake in shares of MDxHealth by 25.7% during the fourth quarter. FreeGulliver LLC now owns 317,894 shares of the company’s stock valued at $1,135,000 after purchasing an additional 65,000 shares in the last quarter. Mink Brook Asset Management LLC lifted its holdings in MDxHealth by 64.9% in the fourth quarter. Mink Brook Asset Management LLC now owns 263,420 shares of the company’s stock worth $940,000 after purchasing an additional 103,686 shares during the period. Renaissance Technologies LLC lifted its holdings in MDxHealth by 23.3% in the fourth quarter. Renaissance Technologies LLC now owns 250,100 shares of the company’s stock worth $893,000 after purchasing an additional 47,300 shares during the period. Finally, Russell Investments Group Ltd. grew its position in MDxHealth by 96.0% in the 4th quarter. Russell Investments Group Ltd. now owns 194,097 shares of the company’s stock valued at $693,000 after buying an additional 95,054 shares in the last quarter.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on MDXH shares. Lake Street Capital cut their price target on MDxHealth from $9.00 to $5.00 and set a “buy” rating on the stock in a report on Thursday. BTIG Research dropped their target price on MDxHealth from $7.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday. TD Cowen reiterated a “buy” rating and issued a $1.50 target price (down from $7.00) on shares of MDxHealth in a research note on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of MDxHealth in a report on Friday, March 27th. Finally, William Blair lowered shares of MDxHealth from an “outperform” rating to a “market perform” rating in a research report on Thursday. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, MDxHealth currently has an average rating of “Moderate Buy” and a consensus price target of $4.63.

Check Out Our Latest Research Report on MDXH

About MDxHealth

(Get Free Report)

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.